SCHEMBL17984699

SCHEMBL17984699

Cn1nc(C(=N)N)c2ccccc21

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 2/20 0.53
ALDH1A1 P00352 1/20 0.47
CYP3A4 P08684 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
HSD17B10 Q99714 1/20 0.47
HTR3A P46098 3/20 0.42
HTR3E A5X5Y0 2/20 0.42
HTR3B O95264 2/20 0.42
HTR3D Q70Z44 2/20 0.42
HTR3C Q8WXA8 2/20 0.42
SLC22A2 O15244 1/20 0.42
CHRNB2 P17787 1/20 0.42
CHRNA3 P32297 1/20 0.42
CHRNA4 P43681 1/20 0.42
KCNH2 Q12809 1/20 0.42
SLC47A1 Q96FL8 1/20 0.42
HDAC3 O15379 1/20 0.41
HDAC1 Q13547 1/20 0.41
ELANE P08246 2/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL260569 0.82 KDM4E (0.60) KDM4EALDH1A1CYP3A4TSHRMAPK1
SCHEMBL29789796 0.82 KDM4E (0.60) KDM4EALDH1A1CYP3A4TSHRMAPK1
SCHEMBL496589 0.76 KDM4E (0.62) KDM4EALDH1A1CYP3A4TSHRMAPK1
SCHEMBL19150070 0.76 KDM4E (0.54) KDM4EALDH1A1CYP3A4TSHRMAPK1
SCHEMBL7297926 0.76 KDM4E (0.62) KDM4EALDH1A1CYP3A4TSHRMAPK1
SCHEMBL30467838 0.76 KDM4E (0.62) KDM4EALDH1A1CYP3A4TSHRMAPK1
SCHEMBL30251861 0.76 KDM4E (0.62) KDM4EALDH1A1CYP3A4TSHRMAPK1
SCHEMBL31632586 0.75 KDM4E (0.60) KDM4EALDH1A1CYP3A4TSHRMAPK1
SCHEMBL992781 0.75 KDM4E (0.60) KDM4EALDH1A1CYP3A4TSHRMAPK1
Hydrochloric Acid SCHEMBL1563376 0.75 KDM4E (0.60) KDM4EALDH1A1CYP3A4TSHRMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2017157991-A1 1-ALKYL-PYRAZOLES AND -INDAZOLES AS BUB1 INHIBITORS FOR THE TREATMENT OF HYPERPROLIFERATIVE DISEASES BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2017-09-21 WO disclosed
US-20160237059-A1 HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-18 US disclosed
US-20160237059-A1 HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-18 US disclosed
US-20160237059-A1 HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2016-08-18 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160237059-A1 HETEROCYCLIC SUBSTITUTED TRIFLUOROMETHYL PYRIMIDINONES AND THEIR USE REN, GLS, FIBP KDM4E 2692/4885ALDH1A1 1089/4885CYP3A4 1801/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.